<DOC>
	<DOCNO>NCT02072161</DOCNO>
	<brief_summary>The purpose research study see ETC-1002 tolerate body ETC-1002 affect level LDL-C ( bad cholesterol ) patient receive ongoing statin therapy .</brief_summary>
	<brief_title>Evaluation ETC-1002 v Placebo Patients Receiving Ongoing Statin Therapy</brief_title>
	<detailed_description>Approximately 132 hypercholesterolemic patient already take statin therapy treat elevate LDL-C randomize ratio 1:1:1 receive either ETC-1002 ( 120 mg 180 mg dose ) , placebo 12 week addition ongoing statin therapy . This study explore safety efficacy ETC-1002 give patient receive statin therapy .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Fasting , calculate mean LDLC ≥130 mg/dL ≤220 mg/dL Fasting mean TG level ≤400 mg/dL Stable statin therapy least 3 month prior screen : atorvastatin ( 10 20 mg daily ) , simvastatin ( 5 , 10 20 mg daily ) , rosuvastatin ( 5 10 mg daily ) , pravastatin ( 10 , 20 40 mg daily ) Clinically significant cardiovascular disease within 12 month screen Current musclerelated symptom may due ongoing statin therapy history certain lab abnormality occur statin therapy resolve statin therapy discontinue Type 1 diabetes uncontrolled type 2 diabetes Use metformin thiazolidinediones ( TZD ) within 4 week screen History chronic musculoskeletal symptom fibromyalgia Uncontrolled hypothyroidism Liver disease dysfunction Renal dysfunction nephritic syndrome Gastrointestinal condition procedure surgery Hematologic coagulation disorder low hemoglobin level HIV AIDS History malignancy History drug alcohol abuse within 2 year Use experimental investigational drug within 30 day screen Use ETC1002 previous clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Statin</keyword>
	<keyword>LDL</keyword>
	<keyword>Cholesterol</keyword>
</DOC>